Disease Overview：Pulmonary Embolism（PE）
Pulmonary embolism (PE) is a life-threatening condition caused by the obstruction of one or more pulmonary arteries—most commonly by thrombi originating from deep vein thrombosis (DVT) in the lower extremities. Clinical presentation ranges from asymptomatic to acute respiratory distress, pleuritic chest pain, hemoptysis, tachycardia, and hypoxemia; severe cases may progress to right heart strain, cardiogenic shock, or sudden death. Diagnosis relies on clinical assessment (e.g., Wells score), D-dimer testing, and confirmatory imaging—primarily CT pulmonary angiography (CTPA) or ventilation-perfusion (V/Q) scintigraphy. Management hinges on risk stratification: anticoagulation (e.g., LMWH, DOACs) for low- to intermediate-risk PE; thrombolysis or catheter-directed therapy for high-risk or submassive PE with hemodynamic compromise; and surgical embolectomy in select refractory cases. Long-term care includes thrombophilia evaluation, duration optimization of anticoagulation, and surveillance for chronic thromboembolic pulmonary hypertension (CTEPH).
China offers distinct advantages in PE management: leading respiratory centers—such as Peking Union Medical College Hospital and Shanghai Pulmonary Hospital—maintain dedicated pulmonary vascular disease units staffed by pulmonologists certified in interventional bronchoscopy and advanced thrombus retrieval techniques. State-of-the-art hybrid operating suites support simultaneous CTPA-guided catheter-directed thrombolysis and mechanical thrombectomy. Five-year survival rates for high-risk PE exceed 85% in top-tier institutions, supported by robust registries and multidisciplinary PE response teams. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based protocols or device quality—many hospitals use FDA-cleared or CE-marked devices identical to those deployed overseas. As a medical tourism agency, we facilitate seamless access for international patients: verifying physician credentials, coordinating appointments at JCI-accredited hospitals, providing itemized, pre-approved cost estimates, arranging visa support, medical translation, and post-discharge follow-up—all within a single, transparent service framework.
Pulmonary Embolism: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Pulmonary Embolism (Respiratory Medicine)
Non-Surgical / Conservative Management
*Indicated for hemodynamically stable patients with low-to-intermediate risk PE (PESI ≤ 65, sPESI ≤ 1, no right heart strain on echo/CT).*
- •Anticoagulation Therapy
- *Direct Oral Anticoagulant (DOAC)*: Rivaroxaban 15 mg BID × 21 days → $135–$192 USD (21-day supply, tiered by brand: domestic generic vs. imported) - *INR Monitoring (for warfarin users)*: PT/INR test × 4 (weekly × 4) → $28 USD
- •Diagnostic & Monitoring Fees
- D-dimer (quantitative ELISA): $12 USD - Arterial Blood Gas (ABG): $18 USD - Transthoracic Echo (TTE): $45–$62 USD
Surgical / Procedural / Interventional Options
*Reserved for massive/high-risk PE (SBP < 90 mmHg, cardiac arrest, refractory hypoxemia) or contraindications to anticoagulation.*
- •Catheter-Directed Thrombolysis (CDT)
- Procedure fee (including catheter, urokinase/tPA infusion, fluoroscopy guidance): $2,150–$2,850 USD - Pre-op workup (ECG, chest X-ray, coagulation panel, renal function): $72 USD
- •Surgical Pulmonary Embolectomy
- Procedure fee (CPB, ICU post-op × 3 days included): $4,900–$6,300 USD - Pre-op workup (CTPA, TTE, ABG, cross-match, anesthesia consult): $210 USD
- •Inferior Vena Cava (IVC) Filter Placement
- Filter device (retrievable stainless steel/nitinol) + fluoroscopic placement: $1,420–$1,880 USD - Retrieval procedure (if indicated at 6–12 weeks): $890 USD
Special/Complex Condition Management
- •Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Confirmed by mPAP ≥25 mmHg + pulmonary vascular resistance ≥3 WU after 3+ months anticoagulation
- *Balloon Pulmonary Angioplasty (BPA)*: Per-session (typically 3–4 sessions): $2,650–$3,400 USD/session
Quick Selection Guide
- •Young, low-risk, budget-conscious (<$200): LMWH → DOAC transition; total cost $175–$260
- •Elderly (>75), high bleeding risk: LMWH monotherapy + strict monitoring; avoid DOACs if CrCl <30 mL/min; total $220–$310
- •Massive PE, no bleeding contraindications: Systemic tPA (100 mg IV over 2 h) + ICU admission ($380–$450) — *lower-cost alternative to CDT*
- •Recurrent PE + anticoagulation failure: IVC filter + long-term DOAC; total $2,000–$2,300
- •Confirmed CTEPH: Refer to PEA-capable center; BPA preferred if distal disease or surgical ineligibility ($7,200–$9,500 or $7,950–$13,600 for full course)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Pulmonary Embolism Medical Vacation Packages
Curated transparent all-inclusive packages combining Pulmonary Embolism treatment with China top medical destinations:
